Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Clinical Trial for a Newly 23-valent Pneumococcal Polysaccharide Vaccine in Chinese Adults and Children

NCT02285036 is registered in ClinicalTrials.gov with Walvax Biotechnology Co., Ltd. as lead sponsor.

NCT NCT02285036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02285036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Clinical Trial for a Newly 23-valent Pneumococcal Polysaccharide Vaccine in Chinese Adults and Children
Lead sponsor
Walvax Biotechnology Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2012
Completion date
May 31, 2013
Enrollment
1,660 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pneumococcal infectious diseases